Русский
Evaluation of immune response checkpoint dynamics in patients with lung cancer receiving immune therapy
DOI: https://dx.doi.org/10.18565/pharmateca.2022.11-12.132-135
A.S. Mochalova
“Medsi Group of Companies”, Medsi Clinical Hospital № 1, Otradnoe, Moscow region, Russia
Objective. Determination of immune response checkpoints and evaluation of the efficacy of immune checkpoint inhibitors in the treat- ment of patients with lung cancer.
Methods. The study included 34 patients (mean age 63.14±3.16 years) with lung cancer and receiving systemic therapy (including surgical treatment): 27 men (mean age 63.63±3.18 years) and 7 women (mean age 61.29±3.09 years). All patients from the moment of inclusion in the study received immunotherapy: PD-1 blocker – nivolumab/pembrolizumab. During the treatment, no clinically significant side effects were noted, the therapy was tolerated satisfactorily. The results of treatment against the background of immunotherapy were evaluated three times during the period of taking the drugs with the analysis of data from a general blood test, a general urinalysis, a biochemical blood test, thoracic computed tomography and immune checkpoints (PD-1, PDL-1, B7-H3, sHLA, CD314-1, sULPB).
Results. In 12 patients (35.29% of cases) stabilization of the pathological process was revealed. The progression of the underlying
disease during therapy was recorded in 14 patients: 11 men (40.74% of cases: stage IV of the disease) and 3 women (42.86% of cases: stage IV of the disease). Progression of the underlying disease during therapy was observed in 14 patients, including 11 men (40,74% of cases: stage IV of the disease) and in 3 women (42,86% of cases: stage IV of the disease). Significantly more patients, both women and men, were alive at the time of completion of the study. There was a pronounced downward trend in the checkpoints indicators B7-H3 and sULPB, an increase in CD314-1, sHLA, PDL-1.
Conclusions. The obtained results indicate the achievement of stabilization of the malignant process in 35.3% of cases in patients with lung cancer on the background of therapy with immune checkpoint inhibitors as part of complex treatment, and create prerequisites for further studies to evaluate them in terms of improving the prognosis of the disease and life.
Methods. The study included 34 patients (mean age 63.14±3.16 years) with lung cancer and receiving systemic therapy (including surgical treatment): 27 men (mean age 63.63±3.18 years) and 7 women (mean age 61.29±3.09 years). All patients from the moment of inclusion in the study received immunotherapy: PD-1 blocker – nivolumab/pembrolizumab. During the treatment, no clinically significant side effects were noted, the therapy was tolerated satisfactorily. The results of treatment against the background of immunotherapy were evaluated three times during the period of taking the drugs with the analysis of data from a general blood test, a general urinalysis, a biochemical blood test, thoracic computed tomography and immune checkpoints (PD-1, PDL-1, B7-H3, sHLA, CD314-1, sULPB).
Results. In 12 patients (35.29% of cases) stabilization of the pathological process was revealed. The progression of the underlying
disease during therapy was recorded in 14 patients: 11 men (40.74% of cases: stage IV of the disease) and 3 women (42.86% of cases: stage IV of the disease). Progression of the underlying disease during therapy was observed in 14 patients, including 11 men (40,74% of cases: stage IV of the disease) and in 3 women (42,86% of cases: stage IV of the disease). Significantly more patients, both women and men, were alive at the time of completion of the study. There was a pronounced downward trend in the checkpoints indicators B7-H3 and sULPB, an increase in CD314-1, sHLA, PDL-1.
Conclusions. The obtained results indicate the achievement of stabilization of the malignant process in 35.3% of cases in patients with lung cancer on the background of therapy with immune checkpoint inhibitors as part of complex treatment, and create prerequisites for further studies to evaluate them in terms of improving the prognosis of the disease and life.
About the Autors
Corresponding author: Anastasia S. Mochalova, Cand. Sci .(Med), Head of the Department of Antitumor Drug Therapy, Medsi Clinical Hospital № 1, Otradnoye, Moscow Region, Russia; denisova.anasatasiya@mail.ru; ORCID: https://orcid.org/0000-0002-7681-5383
Similar Articles
